Abbott has announced results from the PERSIST-END study of its TactiCath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) for persistent atrial fibrillation (AFib), the most common arrhythmia.
The prospective, multi-centre, single-arm clinical trial showed that nearly nine out of ten patients (89%) treated for AFib with the company’s TactiCath SE remained symptom-free for up to 15 months after the procedure.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Additionally, the data showed that patients reported significant quality-of-life improvements and over 50% reduction in the use of health care resources, due to the therapy.
Abbott electrophysiology business chief medical officer Christopher Piorkowski said: “Ablation therapy is an increasingly important option for people living with cardiac arrhythmias because it allows physicians to treat the cause of the arrhythmia at its source.
“We developed TactiCath SE to provide clear information on whether the device is making contact with the heart wall and whether the pressure is enough to achieve the therapeutic goals.
“The outcomes are clear – the system delivers safe and effective results.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTactiCath SE is used as part of a minimally invasive cardiac ablation procedure and in conjunction with Abbott’s EnSite X EP System, the Advisor HD Grid Mapping catheter, and EnSite Omnipolar Technology (OT).
Carried out from 2018 to 2021, the PERSIST-END trial included 224 patients recruited from 21 investigational sites in the US and Australia.
In the trial, subjects were evaluated for 15 months following the cardiac ablation procedure for safety, efficacy, and quality of life measures.
All of the primary safety, effectiveness and quality of life endpoints were met in the trial.
Additionally, as per the overall primary effectiveness endpoint, 61.6% of subjects remained free from any new or increased Class I/III AAD, arrhythmia recurrence, repeat ablation or cardioversion.
